Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00130507
Status:
TERMINATED
Last Update Posted:
2019-02-26
First Post:
2005-08-12
Brief Title:
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
Sponsor:
Spanish Breast Cancer Research Group
Organization:
Spanish Breast Cancer Research Group
Organization Data
Organization:
Spanish Breast Cancer Research Group
Class:
OTHER
Study ID:
GEICAM 2004-06
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Spanish Breast Cancer Research Group
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Hoffmann-La Roche | INDUSTRY |